PROVIREX and Pantherna Therapeutics entered into a research collaboration to develop and evaluate Pantherna’s proprietary PTXxLNP delivery technology based on novel lipid-based mRNA formulations for transfecting CD4+ lymphocytes. PTXxLNP is a promising candidate for the “non-viral“ delivery of PROVIREX’s proprietary antiviral genome editing tool Brec1.